Skip to main content
. 2024 Mar 20;30(11):2412–2423. doi: 10.1158/1078-0432.CCR-23-3940

Figure 3.

Figure 3. Increase of intratumoral T cells post-NOUS-PEV treatment with vaccine-induced T cells infiltrating tumor. A, Expansion and diversification of TCRβ repertoire in pre- and posttreatment tumor biopsies in four NOUS-PEV patients (3 PR;1 SD). Each bar indicates the abundance of individual TCRβ clones detected in the total tumor RNAs extracted from the biopsies collected at the two time points (details in Patients and Methods). B, Total number of TCRβ counts detected in tumor biopsies estimated by summing up the abundance of the individual clones reported in A. The solid lines represent NOUS-PEV patients receiving the full vaccine regimen GAd/MVA; the dashed line represents the patient (Pt 5) who only received MVA-PEV. C, Number of individual clones with different TCRβ CDR3 detected in the patients’ tumor biopsies (*, P ≤ 0.05, paired t test).

Increase of intratumoral T cells post-NOUS-PEV treatment with vaccine-induced T cells infiltrating tumor. A, Expansion and diversification of TCRβ repertoire in pre- and posttreatment tumor biopsies in four NOUS-PEV patients (3 PR;1 SD). Each bar indicates the abundance of individual TCRβ clones detected in the total tumor RNAs extracted from the biopsies collected at the two time points (details in Patients and Methods). B, Total number of TCRβ counts detected in tumor biopsies estimated by summing up the abundance of the individual clones reported in A. The solid lines represent NOUS-PEV patients receiving the full vaccine regimen GAd/MVA; the dashed line represents the patient (Pt 5) who only received MVA-PEV. C, Number of individual clones with different TCRβ CDR3 detected in the patients’ tumor biopsies (*, P ≤ 0.05, paired t test).